Page Banner

United States Department of Agriculture

Agricultural Research Service

You are here: ARS Home / Collaborating / Office of Technology Transfer / Animal Health
Animal Health
headline bar

Each year, approximately 60 new patents are issued by the U.S. Patent Office for USDA inventions. The Office of Technology Transfer (OTT) transfers these inventions through licenses to the private sector for commercialization. Below are links to the new technologies that are available for licensing. 

Docket

Title

Description

Contact

186.11 + 79.14
NEW

HIGH AFFINITY MONOCLONAL ANTIBODIES FOR DETECTION OF SHIGA TOXIN 2 (STX2)

High affinity monoclonal antibodies against Shiga toxin strain Stx2 and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting Stx2 and variants thereof in a sample

 

Potential Commercial Applications

- Basis for developing a sensitive immunoassays for detecting variants for Shiga toxin 2

- Immunoassys could be used for monitoring and source-tracking food supplies as well as monitoring contamination of clinical and environmental samples such as feces, soil, air, and water

 

Competitive Advantages

- The hybridoma cell lines produce monoclonal antibodies that detect all four variants of Stx2

- Immunoassays are rapid, highly specific and sensitive

 david.nicholson@ars.usda.gov

2.14                        NEW

METHOD FOR BED BUG CONTROL

A low oxygen treatment method for bed bug control. The method comprises placing a bed-bug contaminated object in a sealable enclosure and establishing reduced oxygen (<3%) conditions for an amount of time sufficient to control bed bugs

Potential Commercial Applications

- An effective and safe treatment to bed bug problems

 

Competitive Advantages

-Environmental friendly method that does not rely on heat, pesticides or insecticides

- Unlikely to have any negative impact on treated objects

 david.nicholson@ars.usda.gov

35.14                  NEW

INTRAVITREAL INJECTION OF A CHIMERIC PHAGE ENDOLYSIN PLY187; PROTECTION FROM STAPHYLOCOCCUS AUREUS ENDOPHTHALMITIS

A novel antimicrobial protein derived from a virus that infects bacteria has been tested and shown to reduce or eradicate staphylococcal bacteria infecting the eye ball in a mouse model of eye infection. The antimicrobial protein evaluated is Ply187AN-KSH3b, a chimeric phage endolysin derived from the Ply187 prophage. Intravitreal injection in C57BL/6 mouse eyes of chimeric Ply187AN-KSH3b (both at 6 and 12 h post infection) significantly improved the outcome of staphylococcal endophthalmitis, preserved retinal structural integrity, and maintained visual function. Phage lysin treatment significantly reduced the bacterial burden and the levels of inflammatory cytokines and neutrophil infiltration in the eyes

Potential Commercial Applications

-There is a need for antimicrobial treatments into the eyeball to cure staphylococcus infections of the eye, especially following cataract surgery

Competitive Advantages

- Staphylococci are notoriously prone to antibiotic resistance development. This protein works on the outside of the pathogen, thereby avoiding many resistance mechanisms that conventional intracellular antibiotics lack

- This protein works through the digestion of the peptidoglycans which result in the lysis of the bacterial cells. This mode of action is especially important due to the ‘immune privileged’ status of the eye, where unlike most other body cavities, immune cells do not invade

james.poulos@ars.usda.gov

 

 

 

 

 

 

 

 


Last Modified: 2/27/2015
Footer Content Back to Top of Page